B. Riley FBR analyst Mayank Mamtani raised his price target for The Medicines Co. (MDCO) to $95 from $74 and added the shares to FBR's Alpha Generator List. The analyst has "heightened conviction" in inclisiran taking a dominant market share in the anti-PCSK9 marketplace, particularly at the expense of Regeneron's (REGN) Praluent. Mamtani's penetration-share scenario analysis suggests worldwide peak sales of $4.1B to $8.0B. The analyst keeps a Buy rating on The Medicines Co. The stock is yet to still reflect last week's "strong" Phase III Orion program execution and evidence generation on safety, efficacy, and durability of effect to reaffirm inclisiran's differentiated clinical profile, Mamtani tells nivestors in a research note.